NCT06782984 Drug Response Testing and Repurposing Using Glioblastoma Organoid
| NCT ID | NCT06782984 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chungnam National University Hospital |
| Condition | Glioblastoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2021-08-18 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2021-08-18 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including temozolomide, in patients with primary or recurrent glioblastoma. The primary question is whether the patient's response to temozolomide is recapitulated in their corresponding patient-derived glioblastoma organoid (GBO). Patient drug responses are evaluated using survival data, while GBO drug responses are assessed through a drug-response testing platform utilizing cell viability assays. Additionally, this platform is used to explore the potential application of various chemotherapeutic agents.
Eligibility Criteria
Inclusion Criteria: * primary or recurrent glioblastoma * patients treated with standard treatment including surgery and temozolomide based chemoradiation therapy * sufficient tumor sample is available for organoid culture Exclusion Criteria: * patients who are not underwent concurrent chemoradiation therapy (CCRT) following surgery * failed to obtain MRI scan after CCRT * patients refusal
Contact & Investigator
Kyung Hwan Kim, MD, PhD
PRINCIPAL INVESTIGATOR
Department of Neurosurgery, Chungnam National University Hospital
Frequently Asked Questions
Who can join the NCT06782984 clinical trial?
This trial is open to participants of all sexes, studying Glioblastoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06782984 currently recruiting?
Yes, NCT06782984 is actively recruiting participants. Contact the research team at nskhkim@cnuh.co.kr for enrollment information.
Where is the NCT06782984 trial being conducted?
This trial is being conducted at Daejeon, South Korea.
Who is sponsoring the NCT06782984 clinical trial?
NCT06782984 is sponsored by Chungnam National University Hospital. The principal investigator is Kyung Hwan Kim, MD, PhD at Department of Neurosurgery, Chungnam National University Hospital. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.